A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(71 sites)

United States

City of Hope (Adults and Pediatrics), Duarte, California

University of California San Diego Moores Cancer Center (Adults only), La Jolla, California

Loma Linda University Medical Center (Adults only), Loma Linda, California

Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics), Los Angeles, California

UCLA Medical Center (Adults and Pediatrics), Los Angeles, California

University of California Davis Comprehensive Cancer Center (Adults only), Sacramento, California

Yale University (Adults and Pediatrics), New Haven, Connecticut

MedStar Georgetown University Hospital (Adults and Pediatrics), Washington D.C., District of Columbia

University of Florida (Adults and Pediatrics), Gainesville, Florida

University of Miami/Jackson Memorial Hospital (Adults only), Miami, Florida

Winship Cancer Institute (Adults only), Atlanta, Georgia